To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with JavaScript enabled.
This website is not optimized for your browser, as configured.
Collaboration

Patient-Focused Drug Development: A Systematic Approach

If you’ve been following us for a while, you may have noticed that our blog and Twitter content often points out that clinical research involves a partnership among many groups of people: sponsor companies (such as Lilly), study coordinators and principal investigators at clinical research sites, ethical review boards, and, of course, patients. The image we created on Lilly TrialGuide to illustrate the relationship among these various groups is meant to subtly show that the patient is at the center of clinical research. Who is involved in clinical trials

While health care providers may be experts on the clinical aspects of a given medical condition, patients are experts on what it is like to live with their condition. When we are developing a potential new treatment in a specific disease, we need to understand several key points:

  • What does it mean to the patient to have this disease or condition?
  • What do patients experience with this disease or condition?
  • What would a successful treatment look like from the patient’s perspective?

Patients have a unique viewpoint that can provide insights on the outcomes that matter most to them.

  • Severity and frequency of symptoms
  • Impact on daily function and daily life

PROAdapted Bullets 17Apr2019-01

This approach is aligned with upcoming guidance from the U.S. FDA on Patient-Focused Drug Development, or PFDD. PFDD is a systematic approach to help ensure that patients’ experiences, perspectives, needs, and priorities are captured and meaningfully incorporated into the development and evaluation of medical products, at all stages along the way.

For example, we often use patient questionnaires in our clinical research studies to collect information from the patient’s perspective. These patient questionnaires are one form of patient-reported outcomes, or PROs. A PRO is defined as “any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else." Understanding the patient’s viewpoint through measures like PROs can be just as important as data we collect through things like laboratory samples (such as blood, urine, stool, or tissue) and imaging results (such as CT, MRI, or PET scans).

Patients are experts on what it is like to live with their condition, and we are making it a priority to listen to them. Drug development is at its best when we include the patient perspective throughout the process.

Tags: PROs,

Recent Articles

From Alzheimer’s Diagnosis to Advocate

LTGBlogAuthors GuestAuthorIcon 20July2018
Guest Author
January 31st, 20225 minute read

Geri had been involved in research in addition to having a healthcare background. Because of this, after being diagnosed with Alzheimer's she knew that she wanted to participate in a clinical trial.

Committed to Cancer Research

Leigh Anne Naas Headshot
Leigh Anne Naas
September 24th, 20211 minute read

Lilly has a strong legacy in cancer research. Our dedicated oncology team work together to create medicines that make life better for people around the world.

Proud Partners in Breast Cancer Research

Leigh Anne Naas Headshot
Leigh Anne Naas
September 22nd, 20213 minute read

Lilly is proud to foster true partnerships with external stakeholders. By working together to raise awareness of breast cancer research, we can make life better for people around the world.

Recommendations for Decentralized Clinical Trial Capabilities in the Wake of COVID-19

BlogAuthors_Kevin_2Feb2022
Kevin Hudziak
September 15th, 20214 minute read

Tips to implement an effective and successful decentralized clinical trial for multiple touch points.

The COVID-19 Pandemic Changed How Sites Conduct Clinical Trials Forever

BlogAuthors_Kevin_2Feb2022
Kevin Hudziak
July 29th, 20213 minute read

To better understand how various countries adapted to execute clinical trials during a pandemic, we conducted a series of virtual feedback sessions with clinicians from all over the world.

This site is intended for US residents.
This site is intended for US residents.